The effect of treatment on quality of life in patients with acromegaly: a prospective study

in European Journal of Endocrinology

Correspondence should be addressed to R T Netea-Maier; Email:

*(T L C Wolters and S H P P Roerink contributed equally to this work)

Restricted access


Acromegaly has a negative influence on health-related quality of life (HRQoL). Previous studies provide limited information on the course of HRQoL during treatment. This study aims to assess the effect of treatment on the course of HRQoL at six predefined time points.


This prospective study examines HRQoL in treatment-naive patients before and during the first 2.5 years of acromegaly treatment.


Therapy-naive acromegaly patients completed three validated questionnaires (RAND-36, AcroQoL, and the Appearance Self-Esteem (ASE)) at six predetermined time points before, during, and after treatment. Outcomes were correlated to IGF1 levels and disease control status.


Twenty-seven acromegaly patients completed the questionnaires at all time points. After treatment, all patients had controlled acromegaly. Scores of RAND-36 domains General health, Vitality and Health change, and all AcroQoL dimensions (except for Relations) improved during treatment (P ≤ 0.003); the largest changes were detected during the first year. Gender influenced HRQoL scores, since AcroQoL scores significantly improved in males but not in females. Over time, IGF1 levels were negatively correlated with HRQoL. After 2.5 years of follow-up, HRQoL of controlled patients was still lower than in the general population.


HRQoL of acromegaly patients was considerably reduced at diagnosis. Disease control was associated with an improvement of HRQoL scores. Males showed a more pronounced improvement than females. The largest changes were detected in the first year of treatment. However, HRQoL during and after treatment remained impaired in acromegaly patients, emphasizing the need of additional support.

Supplementary Materials

    • Supplementary Table 1 Prospective HRQoL scores
    • Supplementary Table 2. Male-female comparison
    • Supplementary Table 3. Course of treatment & IGF1 levels


     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 151 151 151
Full Text Views 37 37 37
PDF Downloads 30 30 30